Home Start
Lecture
Presentation
Download
Podcast
Enter
Learning Assessment
& Evaluation Form
Download
Activity
Workbook

OVERVIEW
This free activity consists of a lecture presentation, a learning assessment, and an evaluation form. The content of this virtual lecture is derived from a live educational symposium presented on Friday, December 3, 2010 in Orlando, Florida.

MEDIUM: Virtual Lecture
INTERNET RELEASE DATE: January 20, 2011
CE AVAILABLE UNTIL: July 20, 2012 for nurses and social workers.
CME credit is no longer available for this activity.

MEDIUM: Virtual Lecture

Estimated time to complete this activity: 3.5 hours


TARGET AUDIENCE
This activity is designed for hematologists, oncologists, nurses, social workers and other healthcare professionals who wish to enhance their knowledge of advances in research and clinical practice for hematological malignancies. The program subject matter may be of interest to those who provide specialized care in the diagnosis, treatment and monitoring of patients with malignancies such as leukemia, lymphoma or myeloma.


ACTIVITY PURPOSE
This activity is designed to educate hematologists, oncologists, nurses, social workers and other healthcare professionals on the evolving role of the tumor microenvironment in the pathogenesis and management of various malignancies.


STATEMENT OF NEED
Much of the cancer research conducted over the past two decades has focused on the tumor and its various characteristics. However, recent data suggest that the microenvironment in which a tumor originates plays a critical role in tumor propagation as well as the development of drug resistance.1 The National Cancer Institute has launched The Tumor Microenvironment Initiative, which focuses on expanding our current understanding of the role of the tumor microenvironment in cancer initiation, progression and metastases.2

As research continues, the potential for components of the tumor microenvironment to serve as therapeutic targets in the management of hematologic malignancies becomes more promising.
3,4 It is critical that healthcare professionals who treat patients with various hematologic malignancies remain abreast of key findings regarding the importance of the tumor environment and its implications in future research, management and patient outcomes.

1Weinberg RA. Nat Genet.. 2008;40:494-495.
2National Cancer Institute. http://plan2010.cancer.gov/Tumor_Microenvironment.htm. Accessed March 6, 2010.
3Dalton W, Anderson KC. Clin Cancer Res. 2006;12:6603-6610.
4Burger JA, Peled A. Leukemia. 2009;23:43-52.


EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

  • Explain the complex interactions between stromal cells and tumor cells
  • Discuss the role of bone marrow microenvironment in leukemia stem cell survival
  • Describe the mechanisms by which bone marrow stroma can confer net chemotherapy resistance in diverse hematologic malignancies
  • Discuss the therapeutic potential of targeting one or more stromal components to reverse malignant cell resistance to chemotherapy and improve clinical outcomes for hematologic malignancies

FACULTY

Dr. AifantisIannis Aifantis, PhD
Associate Professor, Department of Pathology
New York University School of Medicine Co-Director, Cancer Stem Cell Program
New York University Cancer Institute
Early Career Investigator
Howard Hughes Medical Institute
New York, NY




Dr. RetigMichael P. Rettig, PhD

Research Assistant Professor of Medicine
Section of Bone Marrow Transplant
Division of Oncology
Washington University School of Medicine
St. Louis, MO



Dr. GhobrialIrene M. Ghobrial, MD

Director of Laboratory
Dana-Farber Cancer Institute
Assistant Professor, Department of Medicine
Harvard Medical School
Boston, MA




Sean J. Morrison, PhDSean J. Morrison, PhD

Director, University of Michigan Center for Stem Cell Biology
Professor, Departments of Internal Medicine and Cell and Developmental Biology
Research Professor, Life Sciences Institute
Investigator, Howard Hughes Medical Institute
University of Michigan
Ann Arbor, MI



Dr. StaudtLouis M. Staudt, MD, PhD

Deputy Chief, Metabolism Branch
Center of Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD




PHYSICIAN CONTINUING EDUCATION INFORMATION
CME credit is no longer available for this activity.


METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
To complete this activity and receive a statement of credit, participants must:

  1. Review all contents of this activity
  2. Complete and submit the learning assessment and evaluation form
  3. Score at least 70% on the learning assessment

NURSE AND SOCIAL WORKER CONTINUING EDUCATION INFORMATION
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 3.5 continuing education contact hours through the California Board of Registered Nursing.

The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: December 2011 Ė December 2014. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 3.5 CE clinical clock hours.

Upon successful completion of the entire program, post-test (grade of 70% or higher) and submission of the activity evaluation, a certificate of completion will be issued to you via email or US mail within 30 days.


DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of continuing medical education (CME) activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), RMEI, LLC, Millennium Pharmaceuticals, Inc., Celgene Corporation and Allos Therapeutics do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, RMEI, Millennium Pharmaceuticals, Inc., Celgene Corporation or Allos Therapeutics. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patientís conditions and possible contraindications on dangers in use, review of any applicable manufacturerís product information and comparison with recommendations of other authorities.


STATEMENT OF SUPPORT
This activity is jointly sponsored by RMEI, LLC and Postgraduate Institute for Medicine, and is supported by educational grants from Millennium Pharmaceuticals, Inc., Celgene Corporation and Allos Therapeutics.


FEE INFORMATION
There is no fee for this educational activity.


QUESTIONS AND TECHNICAL ASSISTANCE
For questions regarding the content of this activity, contact the Information Resource Center (IRC) at 800-955-4572, or visit the LLS website at www.LLS.org. For technical assistance, contact jungsen@rmcom.net.


SYSTEM REQUIREMENTS
Hardware/Software requirements include:
• Windows 95, 98se, ME, XP, NT 4.0, 2000   
  - Internet Explorer 4.0+
  - Netscape Navigator 6.2+
  - Mozilla Firefox 1.0+

• Macintosh 9.2, OS X 10.1+
  - Safari 1.1+
  - Netscape Navigator 6.2+
  - Internet Explorer 5.2+
  - Mozilla Firefox 1.0+

• Additional Requirements
  - Windows Media Player
  - Internal/external speakers
  - Broadband connection (DSL/cable) recommended

 

 

RMEI Privacy Statement

Questions, grievances, assistance for people with disabilities or for more information on LLS programs, please contact an LLS Information Specialist at (800) 955-4572.